- Investopedia•15 days ago
Cellectis’ unique gene-edited cell therapy drug gets approval to proceed with early-stage trials.
- Motley Fool•16 days ago
Despite a lack of significant news, this clinical-stage biotech stock had a volatile month.
- Zacks•21 days ago
GlaxoSmithKline plc (GSK) is scheduled to report fourth-quarter 2016 and full-year results on Feb 8. Last quarter, the company delivered a positive earnings surprise of 7.79%.
KITE : Summary for Kite Pharma, Inc. - Yahoo Finance